Customer Stories

Customers are improving their health with insights gained from 23andMe reports. Here are just a few of their stories.


BRCA1/BRCA2 (Selected Variants Genetic Health Risk Report)*
″We all feel tremendously lucky that we could make a decision about our bodies and our health from a place of being healthy.″


Alpha-1 Antitrypsin Deficiency (Genetic Health Risk Report)*
″Finding out this information has probably added years to my life.″


Celiac Disease (Genetic Health Risk Report)*
″I told my doctors I got the 23andMe test, and it just blew their minds.″

HCP Education Videos

Healthcare Professionals provide general insights into the disease of their expertise.

Dr. James K. Stoller

Pulmonary/Critical Care Physician
Chairman, Education Institute at Cleveland Clinic

Alpha-1 Antitrypsin Deficiency (AATD)
″Alpha-1 antitrypsin deficiency is relatively common, very much under recognized, and carries consequences for health risk.″

Dr. Peter H.R. Green

Director, Celiac Disease Center at Columbia University

Celiac Disease
″The most important thing about celiac disease is the recognition that it's very common.″

Questions? Contact us at

*The 23andMe PGS test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child’s risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of BRCA1/BRCA2 variants in the general population. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding other genetic health risk reports and carrier status reports, visit .